2024年McDonald标准应用:多发性硬化早期诊断与避免误诊
本文综述2024年McDonald多发性硬化诊断标准的实质性修订,包括空间多发解剖部位扩展、可替代时间多发的新旁临床指标及无症状或不典型表现患者的诊断路径。修订首次纳入中央静脉征、顺磁性边缘病灶、脑脊液κ游离轻链和光学相干断层扫描等工具,并强调在儿科、血管共病人群及老年患者中减少误诊。全球实施尤其在中低收入国家需教育推广与资源整合。
要点
- 2024标准扩展空间多发部位并新增可替代时间多发的旁临床指标,有助更早诊断。
- 首次纳入中央静脉征、顺磁性边缘病灶、脑脊液κ游离轻链及光学相干断层扫描。
- 对儿科、血管共病及老年患者推荐特定诊断路径以降低误诊风险。
核心结论
- 2024年McDonald标准修订有望实现更早且更准确的多发性硬化诊断,但需专业经验并面临全球实施挑战。
研究设计与样本
- 本文为综述,围绕2024年McDonald标准的关键修订及其在常规临床实践中的应用进行情境化解读,面向全球非专科医生与受训者提供指导。
主要发现
- 修订扩展了代表空间多发的解剖部位,新增可替代时间多发的旁临床发现,并纳入无症状或非特异性临床表现患者。
- 修订统一了典型发作起病与进展起病的诊断路径,并为无症状或非特异性表现伴典型MRI发现者建立新路径。
- 修订继续依赖典型临床与MRI表现识别,并针对儿科、血管共病及老年患者推荐特定方法以减少误诊。
关键数值与推荐
- 2024标准首次纳入MRI中央静脉征、顺磁性边缘病灶、脑脊液κ游离轻链和光学相干断层扫描作为旁临床工具。
- 新路径涵盖无症状或非特异性临床表现伴典型MRI发现的患者。
- 对儿科患者、血管共病患者及老年患者推荐特定诊断方法以降低误诊风险。
临床怎么用
- 临床应依据2024标准识别典型临床与MRI表现,并合理应用新增旁临床工具,对特殊人群采用推荐路径以减少误诊。
- 全球实施需教育推广、利用现有资源并推动卫生系统提高新技术可及性。
局限性
- 既往数据显示存在实施障碍以及对既往修订版的理解不足和误用,可能与误诊相关。
- 全球实施尤其在中低收入国家面临新技术可及性与资源限制的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The evolution of multiple sclerosis (MS) diagnostic criteria over the past 4 decades has shortened the time to diagnosis of MS, enabling earlier institution of immunomodulatory therapy and therefore improved clinical outcomes. In response to a recent expansion of knowledge related to approaches and paraclinical tools that may aid diagnosis of MS and identify causes of MS misdiagnosis, the 2024 McDonald criteria reflect substantive changes and introduce new pathways to MS diagnosis. These revisions carry potential for both earlier and more accurate diagnosis of MS, yet require expertise for their appropriate application in clinical practice and introduce new challenges for global implementation. These changes include expansion of anatomical locations that represent dissemination in space, new paraclinical findings that can substitute for dissemination in time, inclusion of patients with asymptomatic or nonspecific clinical presentations, and recommendations for diagnostic approaches in specific patient populations. These changes also incorporate new paraclinical tools for the first time, including MRI central vein sign and paramagnetic rim lesions, CSF kappa free light chains, and optical coherence tomography. The revised criteria have now unified the diagnostic pathway for clinical presentations typical of MS with attack or progressive onset, and established a new pathway for patients without symptoms or with nonspecific clinical presentations accompanied by MRI findings typical of MS. The 2024 revisions continue to rely on recognition of typical clinical and MRI findings of MS, and additionally recommend specific approaches to pediatric patients, patients with vascular comorbidities, and older patients to further reduce the risk of misdiagnosis. Previous data suggest barriers to implementation, and misunderstanding and misapplication of prior revisions to MS diagnostic criteria that may be associated with misdiagnosis. Implementation of the revised 2024 McDonald criteria globally, particularly in low and low-middle income countries, will require educational outreach, leveraging and maximizing existing resources, and engagement of health care systems to improve access to new technology. This review contextualizes the implications of key revisions in the 2024 criteria for routine clinical care, while providing accessible guidance for its appropriate application with a lens toward nonspecialist clinicians and trainees globally, to ensure early and accurate MS diagnosis.
引用
- Solomon AJ, Brownlee WJ, Viswanathan S, et al. Application of the 2024 McDonald Criteria: Earlier Diagnosis and Avoiding Misdiagnosis of Multiple Sclerosis in a Global Setting. Neurology. 2026. PMID: 42617144. doi:10.1212/WNL.0000000000218425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。